Page 207 - EJMO-9-2

Eurasian Journal of Medicine

and Oncology

ORIGINAL RESEARCH ARTICLE
Tetramethyl thyroxine promotes bladder cancer

development by regulating the expression of
integrin αV, VEGF, and TP53

Wenjing Zhang 1† , Rui Guo 1† , Xiaoyang Chen 1 , Ruolan Chen 1 ,
Jian Dong 1 , Yan Liu 1 , Danning Song 1 , Shangyang Pan 1 ,
1
2
Jianfeng Wang * , and Zhao Yang *
1 College of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation
Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing, China
2 Department of Urology, China-Japan Friendship Hospital, Beijing, China
(This article belongs to the Special Issue: New Developments in Bladder Cancer Treatment and
Management)

Abstract

Bladder cancer (BC) is the most prevalent malignancy of the genitourinary system,
exhibiting the highest morbidity and mortality rates among cancers in this category.
Tetramethyl thyroxine (T4) has been recognized to promote the proliferation of
various cancer cells. However, the possible effect and underlying mechanisms of
† These authors contributed equally
to this work. T4 on the onset and progression of BC remain to be fully elucidated. Our research
demonstrated that T4 significantly promoted the proliferation and migration of EJ-1
*Corresponding authors: and T24 cells. The proliferation of T24 and EJ-1 cells increased by 5 – 28.3% and 4.7 –
Zhao Yang
(yangzhao@mail.buct.edu.cn); 18.7%, respectively. Similarly, the scratch healing rates of T24 and EJ-1 cells increased
Jianfeng Wang by 9.27 – 41.01% and 11.47 – 35.8%, respectively. In addition, apoptosis of T24 and
(2021201142@mail.buct.edu.cn) EJ-1 cells was also significantly reduced after T4 treatment. Furthermore, in vivo
Citation: Zhang W, Guo R, xenograft tumor model further corroborated that T4 facilitated the growth of EJ-1
Chen X, et al. Tetramethyl cell-derived tumors. Our findings indicated that T4 promoted tumor angiogenesis
thyroxine promotes bladder cancer
development by regulating the and cell proliferation by upregulating its receptor integrin αV and vascular
expression of integrin αV, VEGF, endothelial growth factor, while simultaneously suppressed the expression of the
and TP53. Eurasian J Med Oncol. tumor suppressor protein TP53. Collectively, our research has determined the tumor-
2025;9(2):199-212.
doi: 10.36922/EJMO025080037 promoting effect and molecular mechanism of T4 on BC through cell and animal
models. In the future, by further expanding the sample size and pre-clinical design,
Received: February 21, 2025 it is expected to provide new theoretical foundations and potential targets for the
Revised: March 30, 2025 prevention, diagnosis, and treatment of BC.
Accepted: April 2, 2025
Published online: April 17, 2025 Keywords: Bladder cancer; Tetramethyl thyroxine; Proliferation; Migration; Integrin αV
Copyright: © 2025 Author(s).
This is an Open-Access article
distributed under the terms of the
Creative Commons Attribution 1. Introduction
License, permitting distribution,
and reproduction in any medium, Bladder cancer (BC), as one of the top ten most prevalent cancers globally, exhibits the
provided the original work is highest incidence and mortality rates among urogenital system tumors. According to
properly cited.
statistics from the International Agency for Research on Cancer, BC has an incidence rate
Publisher’s Note: AccScience of 3.1%, ranking ninth globally. In 2022, it is estimated that there will be approximately
Publishing remains neutral with
regard to jurisdictional claims in 614,000 new cases and 220,000 deaths attributable to BC, with the incidence rate
published maps and institutional significantly higher in men compared to women. 1
affiliations.

Volume 9 Issue 2 (2025) 199 doi: 10.36922/EJMO025080037